Evidence map›Paper›PMID 31728045›Full record

ArticleScientific reports2019

Dual targeting of IGF-1R and ErbB3 as a potential therapeutic regimen for ovarian cancer.

Adam J Camblin, Gege Tan, Michael D Curley, Isabel Yannatos, Sergio Iadevaia, Victoria Rimkunas, Mari Mino-Kenudson, Troy Bloom, Birgit Schoeberl, Daryl C Drummond and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. HER3 in cancer: from the bench to the bedside.Journal of experimental & clinical cancer research : CR · 2022
    Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Adam J CamblinMerrimack Pharmaceuticals, Inc, Cambridge, MA, USA. adam.camblin@gmail.com.
Gege TanMerrimack Pharmaceuticals, Inc, Cambridge, MA, USA.
Michael D CurleyMerrimack Pharmaceuticals, Inc, Cambridge, MA, USA.
Isabel YannatosMerrimack Pharmaceuticals, Inc, Cambridge, MA, USA.ORCID http://orcid.org/0000-0003-2798-1411
Sergio IadevaiaMerrimack Pharmaceuticals, Inc, Cambridge, MA, USA.
Victoria RimkunasMerrimack Pharmaceuticals, Inc, Cambridge, MA, USA.
Mari Mino-KenudsonMassachusetts General Hospital, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-9092-2265
Troy BloomMerrimack Pharmaceuticals, Inc, Cambridge, MA, USA.
Birgit SchoeberlMerrimack Pharmaceuticals, Inc, Cambridge, MA, USA.
Daryl C DrummondMerrimack Pharmaceuticals, Inc, Cambridge, MA, USA.ORCID http://orcid.org/0000-0001-6803-8863
Alexey A LugovskoyMerrimack Pharmaceuticals, Inc, Cambridge, MA, USA.
Chrystal U LouisMerrimack Pharmaceuticals, Inc, Cambridge, MA, USA.
Vasileios AskoxylakisMerrimack Pharmaceuticals, Inc, Cambridge, MA, USA. v.askoxylakis@gmail.com.
Merrimack Pharmaceuticals (United States) · USHarvard University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Therapeutically targeting receptor tyrosine kinases has proven to be paramount to overcoming chemotherapy resistance in several cancer indications, improving patient outcomes. Insulin-Like Growth Factor Receptor 1 (IGF-1R) and Epidermal Growth Factor Receptor 3 (ErbB3) have been implicated as two such drivers of resistance, however their simultaneous role in ovarian cancer chemotherapy resistance remains poorly elucidated. The aim of this work is to determine the effects of dual IGF-1R/ErbB3 inhibition on ovarian cancer cell signaling, growth, and in vivo efficacy. Assessment of in vitro chemotherapy response across a panel of ovarian cancer cell lines revealed that increased IGF-1R cell surface expression correlates with decreased sensitivity to chemotherapy, and that growth induced by IGF-1R and ErbB3 ligands is blocked by the tetravalent bispecific antibody targeting IGF-1R and ErbB3, istiratumab. In vitro chemotherapy treatment increased ovarian cancer cell line capacity to activate prosurvival PI3K signaling in response to ligand, which could be prevented with istiratumab treatment. Furthermore, in vivo efficacy of standard of care chemotherapies using a xenograft model of ovarian cancer was potentiated with istiratumab. Our results suggest a role for IGF-1R and ErbB3 in driving chemotherapy resistance of ovarian cancer.

Indexed as

AnimalsAntibodies, Monoclonal, HumanizedAntineoplastic AgentsCell Line, TumorCell ProliferationCell SurvivalCisplatinDoxorubicinDrug Resistance, NeoplasmDrug SynergismFemaleGene Expression Regulation, NeoplasticHumansMiceOvarian NeoplasmsPaclitaxelAntibodies, Monoclonal, HumanizedAntineoplastic AgentsCisplatinDoxorubicinERBB3 protein, humanIGF1R protein, humanIstiratumabliposomal doxorubicinPaclitaxelPolyethylene GlycolsReceptor, ErbB-3Receptor, IGF Type 1

Identifiers

PMID31728045
PMCPMC6856132
OpenAlexW2986104336

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.